65G Stock Overview
A biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
NextCell Pharma AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.081 |
| 52 Week High | kr0.38 |
| 52 Week Low | kr0.063 |
| Beta | 0.83 |
| 1 Month Change | 8.53% |
| 3 Month Change | -59.50% |
| 1 Year Change | -77.94% |
| 3 Year Change | -94.69% |
| 5 Year Change | n/a |
| Change since IPO | -95.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| 65G | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 6.8% | 1.7% | -0.2% |
| 1Y | -77.9% | -24.9% | 5.4% |
Return vs Industry: 65G underperformed the German Biotechs industry which returned -24.9% over the past year.
Return vs Market: 65G underperformed the German Market which returned 5.4% over the past year.
Price Volatility
| 65G volatility | |
|---|---|
| 65G Average Weekly Movement | 39.5% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 65G's share price has been volatile over the past 3 months.
Volatility Over Time: 65G's weekly volatility has increased from 21% to 39% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 17 | Mathias Svahn | www.nextcellpharma.com |
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. The company develops ProTrans, a drug candidate that consists of stem cells for the treatment of autoimmune disease, including type-1 diabetes. It also operates Cellaviva, a stem cell bank.
NextCell Pharma AB Fundamentals Summary
| 65G fundamental statistics | |
|---|---|
| Market cap | €11.35m |
| Earnings (TTM) | -€3.42m |
| Revenue (TTM) | €1.33m |
8.5x
P/S Ratio-3.3x
P/E RatioIs 65G overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 65G income statement (TTM) | |
|---|---|
| Revenue | kr15.31m |
| Cost of Revenue | kr10.95m |
| Gross Profit | kr4.36m |
| Other Expenses | kr43.73m |
| Earnings | -kr39.37m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
Jul 25, 2024
| Earnings per share (EPS) | -1.15 |
| Gross Margin | 28.46% |
| Net Profit Margin | -257.21% |
| Debt/Equity Ratio | 0% |
How did 65G perform over the long term?
See historical performance and comparison